Search Results - "DEPLANQUE, G"

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer by Deplanque, G., Demarchi, M., Hebbar, M., Flynn, P., Melichar, B., Atkins, J., Nowara, E., Moyé, L., Piquemal, D., Ritter, D., Dubreuil, P., Mansfield, C.D., Acin, Y., Moussy, A., Hermine, O., Hammel, P.

“…Masitinib is a selective oral tyrosine–kinase inhibitor. The efficacy and safety of masitinib combined with gemcitabine was compared against single-agent…”
Get full text

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial by Durand, J.P., Deplanque, G., Montheil, V., Gornet, J.M., Scotte, F., Mir, O., Cessot, A., Coriat, R., Raymond, E., Mitry, E., Herait, P., Yataghene, Y., Goldwasser, F.

“…Oxaliplatin neurosensory toxicity is dose limiting and may present as acute symptoms and/or cumulative peripheral neuropathy. From October 2005 to May 2008,…”
Get full text

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial by Fléchon, A., Pouessel, D., Ferlay, C., Perol, D., Beuzeboc, P., Gravis, G., Joly, F., Oudard, S., Deplanque, G., Zanetta, S., Fargeot, P., Priou, F., Droz, J.P., Culine, S.

“…In the evolution of metastatic castration-resistant prostate cancer (mCRPC), patients present visceral metastases with or without neuroendocrine…”
Get full text

Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer by Evans, T.R.J., Van Cutsem, E., Moore, M.J., Bazin, I.S., Rosemurgy, A., Bodoky, G., Deplanque, G., Harrison, M., Melichar, B., Pezet, D., Elekes, A., Rock, E., Lin, C., Strauss, L., O’Dwyer, P.J.

“…Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate with limited treatment options. Gemcitabine provides a marginal survival benefit for patients…”
Get full text

P-284NESC Multicenter phase II trial in the Preoperative Treatment of gastric adenocarcinoma consisting of chemotherapy using docetaxel-cisplatin-5FU + lenograstim followed by chemoradiation (RTCT) based 5FU and oxaliplatin and surgery by Mineur, L, Deplanque, G, Desseigne, F, Moureau-Zabotto, L, Boulat, O, Jalali, K, Smith, D, Obled, S, Belkacemi, M

Get full text

2024 Non-interventional study in elderly patients with metastatic colorectal cancer treated with first line bevacizumab combined to chemotherapy in real life: The CASSIOPEE Study - Interim analysis on patients’ characteristics by Francois, E, Kim, S, Deplanque, G, Smith, D, Gourgou, S, Rollot-Trad, F, Gally, S, Berthier, A, Mineur, L

Get full text

Dexrazoxane prevents skin necrosis in non-target embolization of falciform artery during transcatheter arterial chemoembolization (TACE) by Stalder, G., Deplanque, G., Shabafrouz, K., Orcurto, A., Bize, P., Duran, R., Denys, A.

Get full text

Anti-angiogenic agents: clinical trial design and therapies in development by Deplanque, G., Harris, A.L.

“…Development of therapies aimed at inhibiting the growth of new blood vessels is among the most intensively studied approaches to the treatment of cancer…”
Get full text

Efficacy of venlafaxine for the prevention and relief of acute neurotoxicity of oxaliplatin: Results of EFFOX, a randomized, double-blinded, placebo-controlled prospective study by Durand, J. P., Deplanque, G., Gorent, J., Montheil, V., Raymond, E., Scotte, F., Mitry, E., Goldwasser, F.

“…Abstract only 9533 Background: Neurosensory toxicity of oxaliplatin is dose-limiting and presents as two distinct clinical syndromes: acute symptoms and…”
Get full text

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma by DEPLANQUE, G, MADHUSUDAN, S, JONES, P. H, WELLMANN, S, CHRISTODOULOS, K, TALBOT, D. C, GANESAN, T. S, BLANN, A, HARRIS, A. L

“…IM862 is a naturally occurring dipeptide (L-glu-L-trp) with immunomodulatory and antiangiogenic properties. A significant anticancer activity has been reported…”
Get full text

A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients by Viens, P., Petit, T., Yovine, A., Bougnoux, P., Deplanque, G., Cottu, P.-H., Delva, R., Lotz, J.-P., Belle, S. V., Extra, J.-M., Cvitkovic, E.

“…Purpose: A multicentric, phase II study to evaluate the efficacy and safety of the combination paclitaxel and oxaliplatin in patients with platinum-sensitive…”
Get full text

Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents by HAN, C, BRAYBROOKE, J. P, DEPLANQUE, G, TAYLOR, M, MACKINTOSH, D, KAUR, K, SAMOURI, K, GANESAN, T. S, HARRIS, A. L, TALBOT, D. C

“…The aims of this study were to identify prognostic variables for toxicity and survival in patients with cancer participating in phase I clinical trials and…”
Get full text

Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients by Cals, L., Rixe, O., François, E., Favre, R., Merad, L., Deplanque, G., Laadem, A., Juin, P., Bereder, J. M., Bernardini, D., Herait, P.

“…Purpose: To determine maximum tolerated dose, safety and efficacy of weekly 24 h infusional 5-fluorouracil (5-FU) combined alternately with oxaliplatin and…”
Get full text

POD-11.01: Dose Finding and Safety Analysis of Inecalcitol in Combination with Docetaxel-Prednisone Regimen in Hormone-Refractory Prostate Cancer (HRPC) Patients (PTS) by Medioni, J, Deplanque, G, Maurina, T, Ferrero, J, Rodier, J, Raymond, E, Allyon, J, Kalla, S, Dufour-Lamartinie, J, Oudard, S

Get full text

Conflicting effects of caffeine on apoptosis and clonogenic survival of human K1 thyroid carcinoma cell lines with different p53 status after exposure to cisplatin or UVc irradiation by Deplanque, G, Céraline, J, Lapouge, G, Dufour, P, Bergerat, J.-P, Klein-Soyer, C

“…Caffeine has been widely described as a chemo/radiosensitizing agent, presumably by inhibiting DNA repair, and affecting preferentially cells with an altered…”
Get full text

Description of erlotinib-related skin effects management in France. Results of the PRECEDE study by Janus, N, Launay-Vacher, V, Robert, C, Souquet, P-J, Mateus, C, Dreno, B, Deray, G, Morere, J-F, Deplanque, G

“…Dermatological effects are among the most frequent side-effects in patients receiving erlotinib (Tarceva). However, there no official recommendations on the…”
Get full text

Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model by MAH-BECHEREL, M. C. M, CERALINE, J, DEPLANQUE, G, CHENARD, M-P, BERGERAT, J-P, CAZENAVE, J-P, KLEIN-SOYER, C

“…Neovascularisation is a key step in tumour growth and establishment of distant metastases. We have recently demonstrated that the thienopyridine SR 25989 an…”
Get full text

430 Dose finding of inecalcitol, a new VDR agonist, in combination with docetaxel–prednisone regimen for castrate-resistant prostate cancer (HRPC) patients (pts) by Medioni, J, Deplanque, G, Ferrero, J.M, Maurina, T, Rodier, J.M, Raymond, E, Allyon, G, Renaux, S, Dufour-Lamartinie, J.F, Oudard, S

Get full text

7030 Dose finding and safety analysis of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients (pts) by Medioni, J, Deplanque, G, Maurina, T, Ferrero, J.M, Rodier, J.M, Raymond, E, Allyon, J, Kalla, S, Dufour-Lamartinie, J.F, Oudard, S

Get full text

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial by Lavaud, Pernelle, Gravis, Gwenaëlle, Foulon, Stéphanie, Joly, Florence, Oudard, Stéphane, Priou, Frank, Latorzeff, Igor, Mourey, Loïc, Soulié, Michel, Delva, Remy, Krakowski, Ivan, Laguerre, Brigitte, Théodore, Christine, Ferrero, Jean Marc, Beuzeboc, Philippe, Habibian, Muriel, Rolland, Frédéric, Deplanque, Gael, Pouessel, Damien, Zanetta, Sylvie, Berdah, Jean François, Dauba, Jerome, Baciuchka, Marjorie, Platini, Christian, Linassier, Claude, Tubiana-Mathieu, Nicole, Machiels, Jean Pascal, Kouri, Claude El, Ravaud, Alain, Suc, Etienne, Eymard, Jean Christophe, Hasbini, Ali, Bousquet, Guilhem, Culine, Stéphane, Boher, Jean-Marie, Tergemina-Clain, Gabrielle, Legoupil, Clémence, Fizazi, Karim

“…Androgen deprivation therapy (ADT) plus docetaxel is the standard of care in fit men with metastatic castration-naive prostate cancer (mCNPC) following results…”
Get full text